Physician profile
Anton Kosov
NPI 1619321817
$1,863.96
in general payments reported to CMS, 2019-2025
25 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.55 · 2020: $88.76 · 2021: $302 · 2022: $316 · 2023: $352 · 2024: $342 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $265.87 | 2021-2025 | Freestyle Libre, Proclaim |
| Astrazeneca Pharmaceuticals LP | $227.11 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $214.95 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $131.14 | 2020-2025 | |
| Amgen INC. | $116.27 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.81 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $105.68 | 2022-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $93.33 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.88 | 2025 | Caplyta |
| Dexcom, INC. | $86.10 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $58.58 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $44.63 | 2025 | Jornay Pm |
| Vifor Pharma, INC. | $42.58 | 2019 | |
| Sumitomo Pharma America, INC. | $33.92 | 2024 | Gemtesa |
| Apria Healthcare LLC | $31.35 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $28.80 | 2025 | Yupelri |
| Abbvie INC. | $27.80 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.27 | 2024 | Gvoke Hypopen |
| Vertex Pharmaceuticals Incorporated | $19.69 | 2025 | |
| Idorsia Pharmaceuticals US INC | $19.61 | 2023 | Quviviq |
| Exact Sciences Corporation | $18.53 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $18.11 | 2025 | Arexvy, Shingrix, Penmenvy |
| Ultragenyx Pharmaceutical INC. | $17.59 | 2022 | |
| Amarin Pharma, INC. | $17.43 | 2021 | |
| Sanofi Pasteur INC. | $16.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Kosov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.